Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib
暂无分享,去创建一个
Sean M. Grimmond | Peter T. Simpson | Georgia Chenevix-Trench | Kum Kum Khanna | Sunil R. Lakhani | S. Lakhani | N. Waddell | S. Grimmond | G. Chenevix-Trench | K. Khanna | M. Quinn | P. Simpson | F. Al-Ejeh | A. Wiegmans | J. Saunus | S. Cocciardi | W. Shi | Wei Shi | Fares Al-Ejeh | Nic Waddell | Sibylle Cocciardi | E. Tilch | Amy McCart-Reed | Jodi M. Saunus | Darrell C. Bessette | Erik Tilch | Tatjana Seidens | Michael C. J. Quinn | Adrian P. Wiegmans | D. C. Bessette | T. Seidens | Amy McCart-Reed | D. Bessette | Tatjana Seidens | A. McCart-Reed
[1] M. Meyerson,et al. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. , 2009, Cancer research.
[2] Jianmin Wu,et al. Somatic Point Mutation Calling in Low Cellularity Tumors , 2013, PloS one.
[3] S. Henikoff,et al. Predicting deleterious amino acid substitutions. , 2001, Genome research.
[4] R. Wilson,et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[5] N. Hanna. Expression of metastatic potential of tumor cells in young nude mice is correlated with low levels of natural killer cell‐mediated cytotoxicity , 1980, International journal of cancer.
[6] A. Look,et al. Alterations in the PITSLRE protein kinase gene complex on chromosome 1p36 in childhood neuroblastoma , 1994, Nature Genetics.
[7] Krishna R. Kalari,et al. Integrated Analysis of Gene Expression, CpG Island Methylation, and Gene Copy Number in Breast Cancer Cells by Deep Sequencing , 2011, PloS one.
[8] G. Pallesen,et al. Expression of segment-specific antigens in the human nephron and in renal epithelial tumors. , 1988, APMIS. Supplementum.
[9] Henri Tagnon,et al. European Journal of Cancer & Clinical Oncology , 1988 .
[10] A. Gown,et al. Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.
[11] Fred R. Miller,et al. Malignant MCF10CA1 Cell Lines Derived from Premalignant Human Breast Epithelial MCF10AT Cells , 2004, Breast Cancer Research and Treatment.
[12] Xiaoyang Wang,et al. Abnormal expression pattern of the ASPP family of proteins in human non-small cell lung cancer and regulatory functions on apoptosis through p53 by iASPP. , 2012, Oncology reports.
[13] J. Richie,et al. Resistance to intravenous tumor metastases in the athymic nude mouse: a paradoxic response. , 1981, Surgery.
[14] Jae Cheol Lee,et al. Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer , 2013, BMC Cancer.
[15] Richard Durbin,et al. Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .
[16] Y. Yatabe,et al. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer , 2007, Cancer science.
[17] C. Perou,et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma , 2006, Modern Pathology.
[18] P. Tan,et al. Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy , 2011, Breast Cancer Research.
[19] S. Henikoff,et al. Predicting the effects of amino acid substitutions on protein function. , 2006, Annual review of genomics and human genetics.
[20] Jun Ma,et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. , 2011, The Lancet. Oncology.
[21] Kai Ye,et al. Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads , 2009, Bioinform..
[22] Xin Lu,et al. ASPP proteins specifically stimulate the apoptotic function of p53. , 2001, Molecular cell.
[23] J. Trent,et al. Abnormalities in the p34cdc2-related PITSLRE protein kinase gene complex (CDC2L) on chromosome band 1p36 in melanoma. , 1999, Cancer genetics and cytogenetics.
[24] R. Ueda,et al. Aberrant overexpression of 53BP2 mRNA in lung cancer cell lines , 2000, FEBS letters.
[25] T. Mok,et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.
[26] Steven Henikoff,et al. SIFT: predicting amino acid changes that affect protein function , 2003, Nucleic Acids Res..
[27] A. Borkhardt,et al. An ins(X;11)(q24;q23) fuses the MLL and the Septin 6/KIAA0128 gene in an infant with AML‐M2 , 2001, Genes, chromosomes & cancer.
[28] N. Marella,et al. Cytogenetic and cDNA microarray expression analysis of MCF10 human breast cancer progression cell lines. , 2009, Cancer research.
[29] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[30] A. Gemma,et al. F1000 highlights , 2010 .
[31] S. Fox,et al. Mutations in EGFR, BRAF and RAS are rare in triple-negative and basal-like breast cancers from Caucasian women , 2013, Breast Cancer Research and Treatment.
[32] N. Osheroff,et al. MLL-SEPTIN6 fusion recurs in novel translocation of chromosomes 3, X, and 11 in infant acute myelomonocytic leukaemia and in t(X;11) in infant acute myeloid leukaemia, and MLL genomic breakpoint in complex MLL-SEPTIN6 rearrangement is a DNA topoisomerase II cleavage site , 2002, Oncogene.
[33] G. Giaccone,et al. Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells. , 2006, International journal of cancer.
[34] P. Bork,et al. A method and server for predicting damaging missense mutations , 2010, Nature Methods.
[35] D. Weisenburger,et al. Deletion of cell division cycle 2-like 1 gene locus on 1p36 in non-Hodgkin lymphoma. , 1999, Cancer genetics and cytogenetics.
[36] S A Forbes,et al. The Catalogue of Somatic Mutations in Cancer (COSMIC) , 2008, Current protocols in human genetics.
[37] Samuel Leung,et al. Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype , 2008, Clinical Cancer Research.
[38] I. Ellis,et al. Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes , 2009, Clinical Cancer Research.
[39] M. Cronin,et al. Tumor Gene Expression and Prognosis in Breast Cancer Patients with 10 or More Positive Lymph Nodes , 2005, Clinical Cancer Research.
[40] Masahiro Fukuoka,et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] Douglas Macmillan,et al. Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. , 2006, European journal of cancer.
[42] G. Giaccone,et al. Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] Daniel A. Haber,et al. Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways , 2004, Science.
[44] Mitsutaka Kadota,et al. Delineating Genetic Alterations for Tumor Progression in the MCF10A Series of Breast Cancer Cell Lines , 2010, PloS one.
[45] Benjamin E. Gross,et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.
[46] Stephen Fox,et al. HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer , 2010, Breast Cancer Research.
[47] S. Lakhani,et al. Breast cancer stem cells: treatment resistance and therapeutic opportunities. , 2011, Carcinogenesis.
[48] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumours , 2013 .
[49] G. Romieu,et al. Lack of EGFR-activating mutations in European patients with triple-negative breast cancer could emphasise geographic and ethnic variations in breast cancer mutation profiles , 2011, Breast Cancer Research.
[50] Anastasia Ivanova,et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] E. Barillot,et al. Genome Alteration Print (GAP): a tool to visualize and mine complex cancer genomic profiles obtained by SNP arrays , 2009, Genome Biology.
[52] M. Kinoshita,et al. Roles of septins in the mammalian cytokinesis machinery. , 2001, Cell structure and function.
[53] N. Gray,et al. Systematic Kinome shRNA Screening Identifies CDK11 (PITSLRE) Kinase Expression Is Critical for Osteosarcoma Cell Growth and Proliferation , 2012, Clinical Cancer Research.
[54] L. Tanoue. Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR , 2011 .
[55] D. Campana,et al. Copyright � 1995, American Society for Microbiology PITSLRE Protein Kinase Activity Is Associated with Apoptosis , 1994 .
[56] A. Vargas,et al. Treatment of Triple-Negative Breast Cancer Using Anti-EGFR–Directed Radioimmunotherapy Combined with Radiosensitizing Chemotherapy and PARP Inhibitor , 2013, The Journal of Nuclear Medicine.
[57] Masahide Takahashi,et al. p53 apoptotic pathway molecules are frequently and simultaneously altered in nonsmall cell lung carcinoma , 2004, Cancer.
[58] Y. Samuels,et al. ASPP1 and ASPP2: Common Activators of p53 Family Members , 2004, Molecular and Cellular Biology.
[59] Jayanta Debnath,et al. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. , 2003, Methods.
[60] S. Henikoff,et al. Accounting for human polymorphisms predicted to affect protein function. , 2002, Genome research.
[61] Q. Kan,et al. Cyclin-dependent kinase 11 (CDK11) is crucial in the growth of liposarcoma cells. , 2014, Cancer letters.
[62] J. Miller,et al. Predicting the Functional Effect of Amino Acid Substitutions and Indels , 2012, PloS one.
[63] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[64] L. Morrison,et al. PTEN and PIK3CA gene copy numbers and poor outcomes in non-small cell lung cancer patients with gefitinib therapy , 2011, British Journal of Cancer.
[65] Steven J. M. Jones,et al. Circos: an information aesthetic for comparative genomics. , 2009, Genome research.
[66] Michael D. Abràmoff,et al. Image processing with ImageJ , 2004 .
[67] Mirko H. H. Schmidt,et al. Ataxin-2 associates with the endocytosis complex and affects EGF receptor trafficking. , 2008, Cellular signalling.
[68] J. Hudson,et al. In vivo gene expression profile analysis of human breast cancer progression. , 1999, Cancer research.
[69] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[70] Y. Yatabe,et al. Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer , 2010, The FEBS journal.
[71] Xin Lu,et al. ASPP: a new family of oncogenes and tumour suppressor genes , 2007, British Journal of Cancer.
[72] HighWire Press. Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research. , 2002 .
[73] P. Jänne,et al. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. , 2006, The Journal of clinical investigation.
[74] D. Easton,et al. Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival , 2007, Breast Cancer Research.
[75] Mitsutaka Kadota,et al. Identification of novel gene amplifications in breast cancer and coexistence of gene amplification with an activating mutation of PIK3CA. , 2009, Cancer research.
[76] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[77] E. Felip,et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.
[78] Mingming Jia,et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer , 2010, Nucleic Acids Res..
[79] Michael Peyton,et al. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. , 2005, Cancer research.
[80] M. Westphal,et al. Frequent genetic alterations in EGFR- and HER2-driven pathways in breast cancer brain metastases. , 2013, The American journal of pathology.
[81] A. Ashworth,et al. Basal-like breast carcinomas: clinical outcome and response to chemotherapy , 2006, Journal of Clinical Pathology.
[82] Penny A. Johnson,et al. Activity of EGFR, mTOR and PI3K inhibitors in an isogenic breast cell line model , 2014, BMC Research Notes.
[83] J.,et al. The New England Journal of Medicine , 2012 .
[84] Y. Hayashi,et al. SEPTIN6, a human homologue to mouse Septin6, is fused to MLL in infant acute myeloid leukemia with complex chromosomal abnormalities involving 11q23 and Xq24. , 2002, Cancer research.
[85] H. Lazarus,et al. Leukemia-associated antigens in ALL. , 1979, Blood.
[86] S. Henikoff,et al. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm , 2009, Nature Protocols.
[87] J. Easton,et al. Regulated expression of a cell division control-related protein kinase during development. , 1991, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[88] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[89] R. Rees,et al. The effect of the immune status of the TAR mouse on the growth and metastasis of tumour xenografts. , 1987, European journal of cancer & clinical oncology.
[90] K. Jensen,et al. Epidermal growth factor receptor variant III contributes to cancer stem cell phenotypes in invasive breast carcinoma. , 2012, Cancer research.
[91] C. Perou,et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.
[92] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumors , 2012, Nature.
[93] D. Easton,et al. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast , 2006, Histopathology.
[94] S. Toyooka,et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. , 2010, The Lancet. Oncology.
[95] M. DePristo,et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.
[96] William C Hahn,et al. Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants , 2005, PLoS medicine.
[97] F. Miller,et al. MCF10AT: a model for the evolution of cancer from proliferative breast disease. , 1996, The American journal of pathology.
[98] Benjamin E. Gross,et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.
[99] J. Minna,et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. , 2006, Journal of the National Cancer Institute.